Inventor · New York, NY, US

Taha Merghoub

42Patents
7h-index
37Co-inventors
61Inventor score

Filing activity: May 28, 2015 → Mar 21, 2023

Most-cited inventions

PatentTitleAreaCited byStatus
US10280226B2 Anti-GITR antibodies and methods of use thereof Emerging Cross-Sectional Technologies 14 Active
US10155818B2 Anti-GITR antibodies and methods of use thereof Emerging Cross-Sectional Technologies 14 Active
US10548930B2 Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors Chemistry; Metallurgy 13 Active
US10736962B2 Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors Emerging Cross-Sectional Technologies 13 Active
US10259882B2 Anti-OX40 antibodies Physics 11 Active
US10836830B2 Antibodies and methods of use thereof Chemistry; Metallurgy 9 Active
US10639366B2 Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors Chemistry; Metallurgy 8 Active
US10626181B2 Nucleic acids encoding anti-OX40 antibodies Physics 5 Active
US10144779B2 Anti-CTLA-4 antibodies and methods of use thereof Chemistry; Metallurgy 5 Active
US10912831B1 Anti-CTLA-4 antibodies and methods of use thereof Emerging Cross-Sectional Technologies 4 Active
US10479833B2 Anti-CTLA-4 antibodies and methods of use thereof Chemistry; Metallurgy 4 Active
US10512662B2 Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy Chemistry; Metallurgy 4 Active
US10323091B2 Anti-PD-1 antibodies and methods of use thereof Chemistry; Metallurgy 3 Active
US11013802B2 Anti-CTLA-4 antibodies and methods of use thereof Emerging Cross-Sectional Technologies 3 Active
US10577426B2 Anti-GITR antibodies and methods of use thereof Emerging Cross-Sectional Technologies 3 Active
US11285209B2 Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors Emerging Cross-Sectional Technologies 2 Active
US11253560B2 Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors Chemistry; Metallurgy 2 Active
US10800849B2 Anti-GITR antibodies and methods of use thereof Emerging Cross-Sectional Technologies 2 Active
US11986503B2 Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy Chemistry; Metallurgy 1 Active
US11345755B2 Anti-PD-1 antibodies and methods of use thereof Chemistry; Metallurgy 1 Active
US11638755B2 Anti-CTLA-4 antibodies and methods of use thereof Emerging Cross-Sectional Technologies 1 Active
US10829559B2 Anti-GITR antibodies and methods of use thereof Physics 1 Active
US11541087B2 Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy Chemistry; Metallurgy 1 Active
US12036279B2 Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors Emerging Cross-Sectional Technologies 1 Active
US10765711B2 Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human FLT3L or GM-CSF for cancer immunotherapy Chemistry; Metallurgy 1 Active

Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.